Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 27Leukemia, Myeloid, Chronic-Phase 9Leukemia 5Philadelphia Chromosome 4Blast Crisis 4Bronchiolitis Obliterans Syndrome 3Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Breast Neoplasms 2Translocation, Genetic 1Pathologic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Processes × bosutinib × Other hematologic neoplasm × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡